Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
IndustryMay 27, 2026

FDA Extends Decision Deadline for AstraZeneca Breast Cancer Drug After Advisory Panel Opposition

The FDA has extended the decision deadline for AstraZeneca's experimental breast cancer pill following an advisory panel's negative vote on the drug's approval. The delay affects potential formulary decisions for Medicaid managed care organizations that cover cancer treatments. Medicaid MCOs should monitor the FDA's final decision timeline as it will impact prior authorization protocols and specialty pharmacy networks for oncology services. The extension creates uncertainty for health plans developing 2024 drug coverage policies.

Pharmacy · Managed Care

Read the full article at statnews.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.